Overview
Study information
| Network: | HVTN |
| Grant Affiliation: | NA |
| Strategy: | NA |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | Primary analysis complete |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
A worldwide, Phase I, dose-escalating study of the safety, tolerability, and immunogenicity of a 3-dose regimen of the MRKAd5 HIV-1 gag vaccine in healthy adults
Description
HVTN 050 (Merck V520-018) is a Phase I clinical trial to evaluate the safety and immunogenicity of MRKAd5 HIV-1 gag (Ad5).
Sign in to see full information about this study and to download study data.
Products
Product info coming soon!Integrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.